The T cell tropic retrovirus of macaque monkeys simian T lymphotropic virus type III (STLV-III) has morphologic, growth, and antigenic properties indicating that it is related to human T cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV), the etiologic agent of the acquired immune deficiency syndrome (AIDS) of humans. STLV-III has recently been shown to induce an AIDS-like disease in macaque monkeys. In this study the humoral immune responses of six experimentally infected monkeys have been characterized to determine whether certain parameters of the antibody response to the virus might be predictive of the clinical outcome of this infection. Two distinct patterns of antibody responses were found. Four animals that died within 160 d of inoculation developed low titer anti-STLV-III antibody responses that recognized only the viral envelope protein, and progressive declines in total plasma IgG levels and absolute peripheral blood T4 lymphocyte numbers. The two animals that lived longer (one died at 352 d, the other remains alive at 430 d) developed high titer anti-STLV-III antibody responses that recognized both viral envelope and core proteins, increases in total plasma IgG, and a later decrease in number of peripheral blood T4 lymphocytes. Interestingly, the single animal that has remained clinically healthy after infection was the only one to develop detectable STLV-III neutralizing antibodies.
Introduction
Considerable progress has been made in characterizing the antibody responses ofindividuals infected with human T cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV),' the human acquired immune deficiency syndrome (AIDS) virus. The major HTLV-III/LAV-encoded proteins recognized by sera ofinfected individuals (1, 2) and the weak in vitro neutralizing activity of these sera (3, 4) have been defined. However, little information is available that correlates Receivedfor publication 3 April 1986 and in revisedform 9 June 1986.
1. Abbreviations used in this paper: AIDS, acquired immune deficiency syndrome; ELISA, enzyme-linked immunosorbent assay; gp, glycoprotein; HTLV-III/LAV, human T cell lymphotropic virus type III/lymphadenopathy-associated virus; IL-2, interleukin 2; Mm, Macaca mulatta; RT, reverse transcriptase; STLV-III, simian T lymphotropic virus type III.
the nature ofthese antibody responses with clinical disease course in infected individuals. Given the large number of individuals infected with HTLV-III/LAV, it is important to determine whether specific characteristics ofthe humoral immune response to the virus might predict the clinical outcome ofthose infections.
Elucidation of such predictive parameters would be most readily accomplished in an animal model of AIDS in which experimentally infected animals could be regularly and intensively studied. The only animal species shown to be infectable with HTLV-III/LAV is the chimpanzee. However, chimpanzees have developed no signs of disease following infection with the human virus (5) (6) (7) (8) . Thus, while the chimpanzee will be important for the development of an AIDS vaccine, it is not an ideal experimental animal in which to study the viral pathogenesis of AIDS.
A T cell tropic retrovirus with striking similarities to HTLV-III/LAV was recently isolated from macaque monkeys at the New England Regional Primate Research Center (9) . We have called this virus simian T lymphotropic virus type III (STLV-HI) of macaques. Like HTLV-III/LAV, STLV-HII can be isolated from T lymphocytes and grows preferentially in T4+ rather than T8+ lymphocytes (10) . By electron microscopy, mature particles have a cylindrical nucleoid and the virus buds in a fashion typical oftype C retroviruses (9) . Furthermore, STLV-III-and HTLV-III/LAV-encoded proteins are serologically crossreactive (1 1). In preliminary studies with this agent, juvenile rhesus monkeys died with a wasting syndrome, opportunistic infections, a primary retroviral encephalitis, and immunologic abnormalities following STLV-III inoculation (12) . Thus, STLV-III induces an AIDS-like disease in rhesus monkeys.
In this study we have characterized the humoral immune response of rhesus monkeys experimentally infected with STLV-III. This was done to determine whether specific parameters of the antibody response to STLV-III might be predictive of the clinical outcome of this infection. We show that the pattern of the anti-STLV-III antibody response of infected monkeys does correlate with clinical disease course. These patterns of virusspecific antibody response also correlated with changes in levels of both the total plasma immunoglobulin G (IgG) and the absolute peripheral blood T4 cells.
Methods
Animal inoculations. Six juvenile rhesus monkeys were experimentally infected as previously described with STLV-III that was isolated from a rhesus monkey that died with a lymphoma (12) . Each animal was inoculated with 1.7 ml of the same cell-free supernatant of a STLV-IIIinfected interleukin 2 (IL-2)-dependent human peripheral blood lymphocyte culture containing 146,000 cpm/ml reverse transcriptase (RT) activity.
Indirect immunofluorescence. An indirect immunofluorescence staining method was used for detection of plasma antibodies against STLV-III. STLV-III-infected and uninfected H9 cells were used as antigen-expressing and negative control cells. Plasma from animals was inactivated at 560C for 60 min. Smears of infected and uninfected H9 cells were fixed with acetone at room temperature for 7 min, dried, then incubated with plasma at 370C for 45 min. After three washes with phosphate-buffered saline (PBS), these smears were incubated with fluorescein-conjugated goat anti-serum to human polyvalent immunoglobulins (Meloy Laboratories Inc., Springfield, VA) at 370C for 45 min, washed three times with PBS, and examined under a fluorescence microscope.
Enzyme-linked immunosorbent assay (ELISA). STLV-III was harvested from producing Hut-78 cells -72 h after a 1 to 3 split. Cells were removed by centrifugation at 500 g for 15 min and the supernatant was filtered through disposable 0.2-itm Nalgene filters to remove residual cells and debris. Virus was then pelleted at 35,000 g for 180 min in a Beckman type 19 rotor. The supernatant was removed and the virus was resuspended overnight in TNE buffer (20 mM Tris HC1, 100 mM NaCl, 1 mM EDTA, pH 7.5) at 40C. After fractionation by Sepharose 4B column chromatography, purified virus contained in the void volume was pooled and pelleted again by centrifugation (13) . Purified virus was resuspended in 100 ,d of calcium-magnesium-free PBS containing 0.5% Triton X-100 and 0.6 M KC1 for each 1 liter of culture. Lysed virus was stored at -70'C before coating wells of ELISA plates with viral antigen. Virus was diluted 1:1,000 with calcium-magnesium-free PBS and 100 ,ul ofthis was added to each well ofNunc immunoplates. After incubation at room temperature overnight, the plates were rinsed with water and unbound sites were blocked by 10 min incubation with 0.3% bovine serum albumin. The plates were rinsed again with water and stored at 4°C in sealed bags before use.
Plasma diluted with 10% heat-inactivated goat serum, and 0.05% Tween 20 in PBS was incubated in antigen-coated wells for 1 h at room temperature; wells were then rinsed three times with 0.05% Tween 20 in PBS. 100 Ml of alkaline phosphatase-conjugated goat antibody to human IgG was added to each well and incubated for 1 h at room temperature. The wells were rinsed three times again and p-nitrophenyl phosphate substrate, prepared as described by the manufacturer (Kirkegaard and Perry Laboratories, Inc., Gaithersburg, MD), was added. After 30 min, sodium hydroxide was added to a concentration of 0.6 M and the absorbance recorded at 410 nm with a Dynatech 600 microplate reader. Plasma samples were diluted 1:20 followed by serial fourfold dilutions for testing. The antibody titer determined by ELISA was defined as that dilution of plasma that resulted in an optical density reading of <0. 1. Radioimmunoprecipitation. H9 with a 3% stacking gel according to the discontinuous buffer system of Laemmli (14) .
Neutralization. Cell-free STLV-III containing culture supernatants were aliquoted and stored in liquid nitrogen for subsequent use in the neutralization studies. Macaque plasma was heat-inactivated and 0.3 ml, diluted 1:2 with PBS, was mixed with 0.3 ml of various dilutions of supernatant containing virus and incubated at 37°C for 1 h. This mixture was incubated with 2 X 106 human phytohemagglutinin-stimulated peripheral blood lymphocytes (PBL) at 370C for 2 h. Cells were then washed three times with PBS, resuspended in 2.5 ml RPMI 1640 medium containing 10% fetal calf serum and 0.1% recombinant interleukin 2 (IL-2) (kindly provided by E. I. DuPont Nemours, Inc., Wilmington, DE). They were cultured in 24-well plates (NUNC, Boston, MA) at 370C in humidified air with 5% CO2. 1-ml aliquots of culture supernatants were harvested every 3 to 4 d and medium was changed at the same time.
Culture supernatants were filtered and stored at -70'C. RT activities of culture supernatants were measured as previously described (10) . Radioimmunoassay for total plasma IgG quantitation. IgG was purified from normal rhesus monkey serum by ammonium sulfate precipitation and gel filtration through Sephacryl S-300 (Pharmacia Fine Chemicals, Piscataway, NJ). Radioiodination of monkey IgG was performed using the method previously described (15). Monoclonal 
Results
Clinical course of disease. Six juvenile rhesus monkeys were experimentally infected with STLV-III (Table I) (12) . STLV-III was isolated from their plasma at 2 wk and PBL at 17 wk after inoculation (12 (Fig. 1 A) .
Electron microscopic examination of these lesions revealed STLV-III particles in the macrophages (Fig. 1 B) Viral proteins recognized by monkey antibodies. Plasma samples from the six inoculated animals were analyzed using radioimmunoprecipitation oflabeled proteins from infected cells followed by gel electrophoresis to assess the presence ofantibodies that recognize the presumed major virus-encoded proteins of STLV-Ill. As shown in Fig. 3 Mm 127-83, the monkey that has remained healthy, developed earlier and more persistent antibodies to the envelope and core viral antigens. Antibody to gp 160/120 was detected by day 17 postinfection and has persisted. Antibodies to p55 and p27 appeared by day 32, were still detectable on day 329, but were no longer present on day 367 postinoculation. No significant decrease in indirect immunofluorescence anti-STLV-III antibody titer or total plasma IgG levels was noted in plasma samples from Mm 127-83 during that time interval. The gp 160/120, p55, and p27 were the only viral proteins that could be detected using plasma samples from these animals under these experimental conditions. Plasma neutralization studies. We assessed the STLV-III neutralizing activity of plasma samples from the two monkeys that developed high titer antibodies specific for STLV-III (Mm 127-83 and Mm 74-84) ( Table III) . The paired plasma samples used in this study showed the same antibody titer against STLV-III (1:46 by indirect immunofluorescence). The virus isolate utilized for the neutralizing assay was the same as that used to infect the six monkeys. A preliminary titration of the virus-containing supernatant showed that the minimum concentration of supernatant necessary for a productive infection ofthe target cells detectable by RT assay was between a dilution of 1:32 and 1:64. When the virus-containing supernatant was added to the assay at a greater concentration than a 1:10 dilution, neither plasma affected the generation ofRT by the target lymphocytes. (Fig. 4) . The two animals surviving longer than 160 d (Mm 74-84 and Mm 127-83) showed significant increases in total plasma IgG after STLV-III infection. This increase has been maintained in the remaining live animal (Mm 127-83). In Mm 74-84, an increased plasma IgG level was evident at least 250 d postinoculation, but this had markedly declined by the time ofits death. All four animals that died by 160 d postinfection showed significant, progressive decreases in total plasma IgG levels after virus inoculation. No significant change in total plasma protein was associated with the decreases in total plasma IgG in the animals (data not shown). Thus, the changes in total IgG in the plasma of the monkeys did not reflect merely gross changes in plasma protein concentrations. Circulating T4+ lymphocytes. Finally, we sought to determine if these patterns of clinical disease course and humoral immune status correlated with alterations in circulating T4+ lymphocytes in the STLV-III-infected animals (Table IV) . The number of T4+ PBL decreased soon after experimental inoculation with STLV-III in the four monkeys that died rapidly and whose total plasma IgG levels decreased postinfection. While some variability was noted in their numbers of circulating T4+ lymphocytes, three of the four (Mm 91-84, Mm 101-84, and Mm 106-83) demonstrated decreases in T4+ PBL to below the normal 1,000/mm3 (12, 16) postinoculation  T4*  T8   T4  T8  T4  T8  T4  T8  T4  T8  T4  T8 Pre- In this prospective study of six juvenile rhesus monkeys inoculated with STLV-III, two distinct patterns of virus-specific antibody responses were found. The first four animals to die developed low titer anti-STLV-III antibody responses that recognized only the gp 120/160 viral envelope protein. The two that lived longer developed high titer anti-STLV-III antibody responses that recognized both viral envelope and core (p55, p27) proteins. Interestingly, the single animal that has remained clinically healthy was the only one that developed a neutralizing antibody response. While these results suggested a correlation between the nature of the antibody response generated by the STLV-III-infected monkeys and their clinical course, these anti-STLV-III antibody responses in fact also correlated with total plasma IgG levels and the absolute number of peripheral blood T4+ lymphocytes in the monkeys. The four animals that died by 160 d postinfection showed immediate and progressive declines in total plasma IgG levels and a trend toward a decrease in T4+ PBL postinoculation, while the two animals that survived longer showed significant increases in total plasma IgG and no immediate fall in circulating T4+ PBL. Thus, the nature of the antibody response to STLV-III in the six experimentally infected monkeys reflected an even more general impairment of their immune function.
The present studies indicate a number of parallels between the nature of the antibody responses of the rhesus monkeys to STLV-III and that of humans to HTLV-III/LAV. The four monkeys that died shortly after STLV-III infection developed decreased plasma IgG levels and only low titer-specific antibody responses to the virus, a pattern of humoral response atypical for human AIDS. However, the remaining two STLV-III-infected monkeys developed increased plasma IgG levels and a lymphadenopathy syndrome, just as is seen in humans after HTLV-III/LAV infection (19) . While these two animals developed increased plasma IgG levels, suggesting that the regulation of their B cell function was abnormal, they still were capable of generating a high titer STLV-III-specific antibody response. The observation that the two monkeys which had a more chronic disease course were the only inoculated animals that developed antibodies to the core viral antigens is consistent with recent findings in studies of HTLV-III/LAV-infected humans. Those studies suggest that AIDS patients are less likely to have antibodies to the HTLV-III/LAV core antigen than infected individuals with less severe manifestations of disease (20) (21) (22) (23) (24) .
It is also of note that, as with plasma of HTLV-III/LAVinfected humans, no obvious correlation could be made between the anti-STLV-III antibody titer and antibody-neutralizing capacity of plasma from these two monkeys. This model provides a unique system for probing these and other questions related to the pathogenesis of AIDS. The study of virus-specific antibody responses in HTLV-III/LAV-infected humans is complicated by a number of important variables. Even in geographically restricted human populations, various HTLV-III/LAV seropositive individuals have been shown to be infected by structurally distinct isolates of the AIDS virus (25) (26) (27) (28) . Moreover, it is usually impossible to determine the precise time of infection of humans. It is also difficult to perform prospective studies that require frequent, invasive interventions. In contrast, in working with the STLV-III/macaque model for AIDS, animals of like age and environmental exposure can be inoculated simultaneously with a single, known viral isolate and studied prospectively with frequent diagnostic interventions. This model should facilitate study ofthe events in disease pathogenesis that result in the extreme variation in manifestations of AIDS. It should also be useful for vaccine development and anti-viral drug testing for AIDS.
